Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Oncolytics Biotech Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Risks<ref>https://ir.oncolyticsbiotech.com/all-sec-filings/content/0001129928-23-000008/oncyf-20221231.htm</ref> == As with any investment, investing in Oncolytics Biotech carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Oncolytics Biotech is very high. === Risks Related to the Companies Operations === * As a clinical stage pharmaceutical company, the prospects of Oncolytics Biotech is regarded as speculative, it is impossible to predict whether new therapeutics will ultimately prove to be safe and effective in humans or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval * Their current product in development, Pelareorep, is in it's R&D stage for human application, the riskiest stage for a company in the biotechnology industry * If they are unable to establish that Pelareorep is a safe, effective treatment for cancer, they may be required to abandon further development of the product and develop a new business strategy === Risks related to the ability to grow the business === * If a product is approved for sale, product manufacturing at a commercial scale, and significant sales to end users at a commercially reasonable price may not be successful * There can be no assurance that adequate funds will be generated to continue development or will ever achieve significant revenues or profitable operations === Risks related to government laws and regulations === * Human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy in order to obtain regulatory approvals for products being developed for human use, and to achieve commercial success * In developing a pharmaceutical product, there is a reliance on employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required === Risks related to the ownership of the company's common stock === * Market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress made__INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)